Nobuhiro Tsukada
Overview
Explore the profile of Nobuhiro Tsukada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
825
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kunisada K, Ogura M, Oda Y, Yogo M, Takei T, Sato K, et al.
Rinsho Ketsueki
. 2025 Feb;
66(1):18-23.
PMID: 39924202
[Patient] A 65-year-old man. [History of present illness] An abnormal chest shadow was noted in March of 2011, and hoarseness was observed in November of 2017. Both times, AL amyloidosis...
2.
Kikuchi T, Kunisada K, Sato K, Tsukada N, Ishida T
Cureus
. 2025 Jan;
16(12):e74902.
PMID: 39744308
Elranatamab is an effective drug for triple-class-exposed relapsed/refractory multiple myeloma (TCE-RRMM). In the pivotal study, only grade 1 or 2 immune effector cell-associated neurotoxicity syndrome (ICANS) were reported, and the...
3.
Sunami K, Iida S, Tsukada N, Fujii T, Kato H, Fukushima R, et al.
Int J Hematol
. 2024 Dec;
121(2):174-186.
PMID: 39718747
DREAMM-11 (NCT03828292) was a Phase 1, open-label, dose-escalation study of belantamab mafodotin in Japanese patients with relapsed/refractory multiple myeloma (RRMM). In Part 1, belantamab mafodotin monotherapy (2.5 or 3.4 mg/kg...
4.
Kikuchi T, Tsukada N, Kunisada K, Nomura-Yogo M, Ishida T
Cureus
. 2024 Nov;
16(10):e72364.
PMID: 39588407
Chimeric antigen receptor T-cell (CAR-T) therapy targeting the B-cell maturation antigen (BCMA) is an effective treatment for patients with relapsed/refractory multiple myeloma (RRMM). However, cytokine release syndrome (CRS) represents a...
5.
Shimizu H, Kato J, Tanoue S, Kimura S, Tachibana T, Hatano K, et al.
Leuk Res
. 2024 Aug;
144:107562.
PMID: 39178610
To investigate the safety of total body irradiation-based myeloablative conditioning (TBI-MAC) in adolescent and young adult (AYA) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) patients treated with pediatric protocols, treatment...
6.
Quach H, Parmar G, Ocio E, Prince H, Oriol A, Crowther H, et al.
Haematologica
. 2024 Aug;
109(12):4078-4082.
PMID: 39157871
No abstract available.
7.
Kikuchi T, Tsukada N, Kunisada K, Matsumoto C, Nomura-Yogo M, Oda Y, et al.
Hematol Oncol
. 2024 Aug;
42(5):e3306.
PMID: 39120040
No abstract available.
8.
Tsukada N, Yogo M, Kunisada K, Oda Y, Takei T, Sato K, et al.
Rinsho Ketsueki
. 2024 Aug;
65(7):615-621.
PMID: 39098010
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a curative treatment option for multiple myeloma (MM), but few patients are eligible due to its high risk of treatment-related toxicity and relapse....
9.
Araki M, Mitsuhashi T, Yatabe Y, Arai T, Yokota H, Okita H, et al.
Clin Chem Lab Med
. 2024 Aug;
PMID: 39097836
No abstract available.
10.
Kikuchi T, Oda Y, Kondo U, Tsukada N, Kunisada K, Matsumoto C, et al.
Hematol Oncol
. 2024 Aug;
42(5):e3302.
PMID: 39096249
To retrospectively analyze whether the second revision of the international staging system (R2-ISS) influenced prognosis at treatment initiation in patients with multiple myeloma (MM) receiving anti-CD38 antibody-based triplet treatments. High-risk...